tbuckley/cabot-search huggingface dataset:
Clinical findings and medical management of hereditary breast-ovarian cancer without molecular diagnosis in a referral cancer center.
Authors: Flavia Morales-Vasquez, Horacio Noe López-Basave, Hector M Caballero, Maria del Carmen Mendez Herrera, Laura Leticia Tirado Gomez, Dolores Gallardo Rincon, Eva Ruvalcaba Limon, MaryTere Herrera, Lorena Urzua, Silvio A Namendys-Silva, Silvia Vidal
Journal: Journal of Clinical Oncology (2012)

e15527 Background: Ovarian cancer is the leading cause of death from gynecologic malignancies. Women at high risk of hereditary breast and/or ovarian cancer (HBOC) require specific management strategies. The goal of this study was to determine the prevalence of HBOC among patients in a referral cancer center. To analyze the pathologic and clinical characteristics of HBOC and examine whether survival is influenced by family history of breast or ovarian cancer. Methods: This retrospective study included all epithelial ovarian cancers seen at the National Cancer Institute of México from 2000-2009. Epidemiological and clinical variables were collected from the patients' medical records. Results: In 1071 cases, we found 15 patients with HBOC. The first pathology was breast cancer, and the ovarian cancer was diagnosed in average 8.23 years later. Only in 2 patients the ovarian cancer was before than breast cancer. The median age was 53 (35-69) years old at diagnosis for breast cancer and 51(40-75) years old in ovarian cancer. The advanced clinical stage was 13% for breast cancer versus 60% for the ovarian cancer. The histology was ductal carcinoma for breast cancer and serous papillary carcinoma for ovarian cancer with high grade. The recurrent disease was frequent for ovarian cancer. The median overall survival was 8 years (1-20 years). Conclusions: Recognition of when ovarian cancer is a substantial risk (in BRCA1 and BRCA2 carriers) is essential. However, the appropriate intervention is difficult to judge, and careful balancing is needed.
Preoperative Posturing of Patients with Macula-On Retinal Detachment Reduces Progression Toward the Fovea
Authors: Jan H. de Jong, Juan P. Vigueras-Guillén, Tiarah C. Simon, Reinier Timman, Tunde Peto, Koenraad A. Vermeer, Jan C. van Meurs
Journal: Ophthalmology (2017)

Traditionally, preoperative posturing consisting of bed rest and positioning is prescribed to patients with macula-on retinal detachment (RD) to prevent RD progression and detachment of the fovea. Execution of such advice can be cumbersome and expensive. This study aimed to investigate if preoperative posturing affects the progression of RD.Prospective cohort study.Ninety-eight patients with macula-on RD were included. Inclusion criteria were volume optical coherence tomography (OCT) scans could be obtained with sufficient quality; and the smallest distance from the fovea to the detachment border was 1.25 mm or more.Patients were admitted to the ward for bed rest in anticipation of surgery and were positioned on the side where the RD was mainly located. At baseline and before and after each interruption for meals or toilet visits, a 37°×45° OCT volume scan was performed using a wide-angle Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany). The distance between the nearest point of the RD border and fovea was measured using a custom-built measuring tool.The RD border displacement and the average RD border displacement velocity moving toward (negative) or away (positive) from the fovea were determined for intervals of posturing and interruptions.The median duration of intervals of posturing was 3.0 hours (interquartile range [IQR], 1.8-14.0 hours; n = 202) and of interruptions 0.37 hours (IQR, 0.26-0.50 hours; n = 197). The median RD border displacement was 2 μm (IQR, -65 to +251 μm) during posturing and -61 μm (IQR, -140 to 0 μm) during interruptions, a statistically significant difference (P < 0.001, Mann-Whitney U test). The median RD border displacement velocity was +1 μm/hour (IQR, -21 to +49 μm/hour) during posturing and -149 μm/hour (IQR, -406 to +1 μm/hour) during interruptions, a statistically significant difference (P < 0.001).By making use of usual interruptions of preoperative posturing we were able to show, in a prospective and ethically acceptable manner, that RD stabilizes during posturing and progresses during interruptions in patients with macula-on RD. Preoperative posturing is effective in reducing progression of RD.
Liver transplantation for human immunodeficiency virus-Infected patients with hepatocellular carcinoma
Authors: C. Citti, D. Pinato, M. Ventura-Cots, H. Platt, M. Merli, B. Minguez, A.D. Pria, R. Sharma, S. Marcus, M. Nelson, M. Bower, V. Mazzaferro, N. Bräu
Journal: Journal of Hepatology (2017)
Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor
Authors: Serafim Kiriakidis, Simon S. Hoer, Natalie Burrows, Gloria Biddlecome, Moddasar N. Khan, Cyrille C. Thinnes, Christopher J. Schofield, Norma Rogers, Marina Botto, Ewa Paleolog, Patrick H. Maxwell
Journal: Kidney International (2017)

Complement C1q is part of the C1 macromolecular complex that mediates the classical complement activation pathway: a major arm of innate immune defense. C1q is composed of A, B, and C chains that require post-translational prolyl 4-hydroxylation of their N-terminal collagen-like domain to enable the formation of the functional triple helical multimers. The prolyl 4-hydroxylase(s) that hydroxylate C1q have not previously been identified. Recognized prolyl 4-hydroxylases include collagen prolyl-4-hydroxylases (CP4H) and the more recently described prolyl hydroxylase domain (PHD) enzymes that act as oxygen sensors regulating hypoxia-inducible factor (HIF). We show that several small-molecule prolyl hydroxylase inhibitors that activate HIF also potently suppress C1q secretion by human macrophages. However, reducing oxygenation to a level that activates HIF does not compromise C1q hydroxylation. In vitro studies showed that a C1q A chain peptide is not a substrate for PHD2 but is a substrate for CP4H1. Circulating levels of C1q did not differ between wild-type mice or mice with genetic deficits in PHD enzymes, but were reduced by prolyl hydroxylase inhibitors. Thus, C1q is hydroxylated by CP4H, but not the structurally related PHD hydroxylases. Hence, reduction of C1q levels may be an important off-target side effect of small molecule PHD inhibitors developed as treatments for renal anemia.
Abstract 185: Muscle Enriched A-Type Lamin Interacting Protein (MLIP) mediates growth and function of the adult heart
Authors: Marie-Elodie Cattin, Stephanie L Thorn, Jessica Wang, Christoph Rau, Esther W Mak, Jean N DaSilva, Jake Lusis, Patrick G Burgon
Journal: Circulation Research (2013)

The newly discovered Muscle-enriched A-type lamin interacting protein (MLIP) is abundantly expressed in the heart. Its biological function remains elusive but it may be of high relevance for cardiac function as it has no paralogous homologue suggesting no functional redundancy. To elucidate MLIP’s function, we generated both hemizygous MLIP and homozygous MLIP null mice. At 8 weeks of age, they both develop dilated cardiomyopathy characterized by enlarged hearts (heart to body weights MLIP+/+ 5.62mg/g vs MLIP+/- 10.73mg/g &amp; MLIP -/- 11.03mg/g) that are functionally dilated (LVDD : +/+ 2.89mm; +/- 3.93mm; -/- 4.11mm) with reduced function (LVFS : +/+ 47%; +/- 31%; -/- 29%). Histological analysis shows no overt abnormalities for both MLIP+/- and MLIP-/- hearts. Preliminary data indicate a preserved cardiomyocyte size in MLIP+/- and MLIP-/- mice, suggesting that the increase in heart size might be due to hyperplasia rather than cellular hypertrophy. Moreover, cardiac gene expression of 12 week-old MLIP+/- and MLIP-/- mice reveals an involvement in pathways associated with cell cycle control and growth. Specifically both gene expression and western analysis demonstrated that the mTORC1 pathway, that promotes protein synthesis and cell growth in response to mitogenic signal, was dysregulated in MLIP null mice. To further characterize these growth pathways the MLIP +/+ MLIP +/- and MLIP -/- mice (n = 3-5/group) were treated with 20 μg/g/day of isoproterenol through an abdominally implanted Alzet micropump for 3 weeks to induce heart failure. All mice went under echocardiographic analysis and were characterized by western, gene expression and histological analysis. Our preliminary data reveal that MLIP null mice are resistant to isoproterenol-induced heart failure as their hearts showed no increase in mass, unlike the significant (p&lt;0.01) increase in heart mass observed in both the control mice (31%) or the MLIP hemizygous mice (19%). No cardiac remodeling was observed in either the MLIP hemizygous or null mice in response to the isoproterenol treatment. In conclusion, MLIP is a newly discovered protein that impacts key pathways involved in cardiac growth and function of an adult heart failure model.
Mother’s Day for Women in Medicine—Better Than Roses
Authors: Marcia Angell, Lara Goitein
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Candida and Chronic Prostatitis
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence of liver steatosis in subjects with risk factors for nonalcoholic fatty liver disease in primary care using controlled attenuation parameter (CAP). A population-based study
Authors: N. Fabrellas, R. Hernandez, E. Solà, A. Coiduras, P. Ramos, I. Graupera, N. Martin, T. Graells, C. Simon, I. Duaso, M. Garcia, A. Larrañaga, A. Perez, C. Sole, P. Huelin, R. Moreira, G. De Prada, P. Ginés
Journal: Journal of Hepatology (2017)
Epidemiology, treatment (tx) patterns and outcomes in Asian soft tissue sarcoma (STS) patients: Results from the Soft Tissue Sarcoma in the Asia Pacific Region (STAR) study.
Authors: Richard Hong Hui Quek, Mohamad Farid, Edward Wang, Apichat Asavamongkolkul, Alex Leung, Nugroho Prayogo, Thipachart Punyaratabandhu, Ee-Min Yeoh, Sumitra Shantakumar, Stephanie Manson, Roger K.C. Ngan
Journal: Journal of Clinical Oncology (2015)

10549 Background: There is a paucity of STS epidemiology and tx pattern information in the Asia Pacific region, with published data only from small or single country studies. STAR, a large multicountry observational study, was initiated to describe epidemiology, tx patterns and clinical outcomes in STS patients (pts) diagnosed in 2006–2010 at tertiary referral centers in Hong Kong, Indonesia, the Philippines, Singapore and Thailand. Methods: Data were collected by retrospective chart review. Kaposi’s sarcoma, gastrointestinal stromal tumor, dermatofibrosarcoma protuberans, bone sarcoma and extraskeletal osteosarcoma were excluded. Demographics, tumor characteristics and tx patterns were analyzed descriptively. Overall survival (OS) and progression free survival (PFS) were estimated by the Kaplan Meier method. Results: STAR included 635 adult pts, 25% of whom presented with metastatic STS. Main histological subtypes: leiomyosarcoma (19%), liposarcoma (19%), undifferentiated pleomorphic sarcoma (UPS; 18%), synovial sarcoma (9%) and angiosarcoma (7%). Of 230 pts who had chemotherapy (CTx), 32% had neoadjuvant or adjuvant CTx only and 68% had palliative CTx. In the palliative setting, most pts had 1 (57%) or 2 (27%) lines of systemic tx. Combination CTx was more common than monotherapy (54% vs 47% of regimens). The most common first line (1L) regimens were doxorubicin/ifosfamide (36%) and paclitaxel (10%). The most common 2L regimens were gemcitabine/docetaxel (29%), gemcitabine (9%) and trabectedin (9%). Median PFS (95% CI) for 1L, 2L and 3L palliative CTx were 3.8 (2.2–5.5) months, 4.0 (2.1–5.8) months and 1.9 (1.3–2.6) months, respectively. Median OS of pts who presented with metastatic STS was 11.7 (8.9–14.5) months. Conclusions: STAR is the first large observational study to capture STS epidemiology, tx patterns and outcomes across Asia. UPS prevalence was similar to published data, suggesting acceptable pathologic quality, while angiosarcoma prevalence appeared slightly higher than in Western studies. During this period, most CTx regimens were combinations and palliative CTx beyond 2L was uncommon. Funding: GlaxoSmithKline.
Analysis of shear wave elastography and serum autotaxin as novel non-invasive markers of liver fibrosis in patients with autoimmune hepatitis – a prospective study
Authors: M.K. Janik, B. Kruk, K. Kostrzewa, J. Raszeja-Wyszomirska, K. Wolf, F. Lammert, A.E. Kremer, M. Krawczyk, P. Milkiewicz
Journal: Journal of Hepatology (2017)
Endoscopic treatment in patients with primary sclerosing cholangitis and established cirrhosis is not associated with an increased rate of complications
Authors: D. Reiners, M. Peiseler, R. Zenouzi, M. Sebode, F. Jung, J. Hartl, H. Ehlken, S. Huebener, S. Groth, U. Denzer, G. Schachschal, T. Roesch, C. Weiler-Normann, A.W. Lohse, C. Schramm
Journal: Journal of Hepatology (2017)
PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynecologic neoplasms: ANZGOG 0903.
Authors: Michael Friedlander, Katrin Marie Sjoquist, Dirkje Willemien Sommeijer, Lisa Bailey, Julie Martyn, Kim Gillies, Linda R. Mileshkin, Rachel O'Connel, Val Gebski, Michelle Margaret Vaughan, Penny Blomfield, Philip James Beale, Michael Quinn, Martin R. Stockler, Janine Margaret Lombard, Alison Maree Hadley, Frederic Amant, Richard J Edmondson
Journal: Journal of Clinical Oncology (2013)

TPS5614 Background: Many gynaecological cancers of different pathological type express estrogen and/or progesterone hormone receptors (ER/PR). Reports of tumour response and clinical benefit with hormonal therapies show variable rates of activity. There is a need to prospectively study the role of aromatase inhibitors in women with potentially hormone responsive recurrent gynaecological cancers to establish response rates, clinical benefit, quality of life (QoL) and identify predictors of response. Methods: PARAGON is phase II Gynecologic Cancer InterGroup trial lead by the Australia New Zealand Gynaecological Oncology Group, Cancer Research UK and the Belgian Gynaecological Oncology Group. The study is designed to facilitate research in rare tumours. The protocol allows postmenopausal women with recurrent gynaecological cancers to enrol into one of 7 subgroups; epithelial ovarian cancer (EOC) with only rising CA125 after first line chemotherapy, platinum resistant/refractory EOC, low grade EOC, endometrial carcinomas, endometrial stromal sarcomas, miscellaneous sarcomas and granulosa cell tumours and other sex cord stromal tumours. ER/PR positivity must be confirmed by immunohistochemistry. Each subgroup will enrol 25-50 patients with defined stopping rules based on response and reviewed by independent data monitoring committee (IDMC). Eligible patients receive 1 mg anastrozole daily until disease progression or unacceptable toxicity. Primary objective: clinical benefit (partial or complete response or stable disease). Secondary objectives: progression free survival, response duration, QoL, toxicity. Blood and tumour samples are being collected for translational studies and confirmation of ER/PR positivity. Recruitment commenced in 2011 in Australia, New Zealand and the United Kingdom. One hundred and fourteen of 350 planned patients have been enrolled to January 2013. In November 2012 IDMC recommended continuing recruitment to the EOC with rising Ca125 only and resistant/refractory subgroups based on review of activity outcomes for the first 25 patients. The trial will open in Belgium in April 2013. ACTRN12610000796088 Clinical trial information: 12610000796088.
CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies
Authors: Mohamad F. Al Sayed, Carla A. Ruckstuhl, Tamara Hilmenyuk, Christina Claus, Jean-Pierre Bourquin, Beat C. Bornhauser, Ramin Radpour, Carsten Riether, Adrian F. Ochsenbein
Journal: Blood (2017)
Serum HBV RNA level monitoring for response prediction in HBeAg positive chronic hepatitis B infection
Authors: M.J. van Campenhout, F. van Bömmel, M. Grossmann, J.J. Fischer, D. Deichsel, A. Boonstra, A.J. van Vuuren, T. Berg, B.E. Hansen, H.L. Janssen
Journal: Journal of Hepatology (2017)
Vena Cava Filter Use in Trauma and Rates of Pulmonary Embolism, 2003-2015
Authors: Alan D. Cook, Brian W. Gross, Turner M. Osler, Katelyn J. Rittenhouse, Eric H. Bradburn, Steven R. Shackford, Frederick B. Rogers
Journal: JAMA Surgery (2017)

Vena cava filter (VCF) placement for pulmonary embolism (PE) prophylaxis in trauma is controversial. Limited research exists detailing trends in VCF use and occurrence of PE over time.To analyze state and nationwide temporal trends in VCF placement and PE occurrence from 2003 to 2015 using available data sets.A retrospective trauma cohort study was conducted using data from the Pennsylvania Trauma Outcome Study (PTOS) (461 974 patients from 2003 to 2015), the National Trauma Data Bank (NTDB) (5 755 095 patients from 2003 to 2014), and the National (Nationwide) Inpatient Sample (NIS) (24 449 476 patients from 2003 to 2013) databases.Temporal trends in VCF placement and PE rates, filter type (prophylactic or therapeutic), and established predictors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paralysis, venous injury, lower extremity fracture, pelvic fracture, central line, intracranial hemorrhage, and blood transfusion). Prophylactic filters were defined as VCFs placed before or without an existing PE, while therapeutic filters were defined as VCFs placed after a PE.Of the 461 974 patients in PTOS, the mean (SD) age was 47.2 (26.4) and 61.6% (284 621) were men; of the 5 755 095 patients in NTDB, the mean age (SD) was 42.0 (24.3) and 63.7% (3 666 504) were men; and of the 24 449 476 patients in NIS, the mean (SD) age was 58.0 (25.2) and 49.7% (12 160 231) were men. Of patients receiving a filter (11 405 in the PTOS, 71 029 in the NTDB, and 189 957 in the NIS), most were prophylactic VCFs (93.6% in the PTOS, 93.5% in the NTDB, and 93.3% in the NIS). Unadjusted and adjusted temporal trends for the PTOS and NTDB showed initial increases in filter placement followed by significant declines (unadjusted reductions in VCF placement rates, 76.8% in the PTOS and 53.3% in the NTDB). The NIS demonstrated a similar unadjusted trend, with a slight increase and modest decline (22.2%) in VCF placement rates over time; however, adjusted trends showed a slight but significant increase in filter rates. Adjusted PE rates for the PTOS and NTDB showed significant initial increases followed by slight decreases, with limited variation during the declining filter use periods. The NIS showed an initial increase in PE rates followed by a period of stagnation.Despite a precipitous decline of VCF use in trauma, PE rates remained unchanged during this period. Taking this association into consideration, VCFs may have limited utility in influencing rates of PE. More judicious identification of at-risk patients is warranted to determine individuals who would most benefit from a VCF.
Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results
Authors: L. Wei, J. Hou, Y. Luo, J. Heo, C.-J. Chu, Z. Duan, M. Cho, J. Cheng, J. Li, J. Jia, W. Lu, L.M. Fredrick, T. Pilot-Matias, N. Mobashery, W.-L. Chuang
Journal: Journal of Hepatology (2017)